ALK and neuroblastoma: Examples include the incorporation of crizotinib along with chemotherapy for patients with newly diagnosed ALK-altered high-risk neuroblastoma (NCT03126916, Table 2) and the randomized phase II screening trial of ifosfamide/doxorubicin with or without pazopanib in newly diagnosed non-rhabdomyosarcoma soft tissue sarcoma [51].